methylphenidate has been researched along with Conduct Disorder in 43 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Conduct Disorder: A repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate societal norms or rules are violated. These behaviors include aggressive conduct that causes or threatens physical harm to other people or animals, nonaggressive conduct that causes property loss or damage, deceitfulness or theft, and serious violations of rules. The onset is before age 18. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the safety and efficacy of adding the atypical antipsychotic quetiapine to ongoing OROS methylphenidate treatment for adolescents with comorbid ADHD and severe aggression that were incompletely responsive to methylphenidate monotherapy." | 9.12 | Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. ( Bohnstedt, BN; Dunn, DW; Giauque, AL; Kronenberger, WG; Lafata, DE; Maxey, LE, 2007) |
| "A pilot comparison of the safety and efficacy of methylphenidate (MPH) combined with clonidine, clonidine monotherapy, or MPH monotherapy in 6- to 16-year-old children diagnosed with attention deficit hyperactivity disorder (ADHD) and comorbid aggressive oppositional defiant disorder or conduct disorder was completed." | 9.09 | A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. ( Barkley, RA; Connor, DF; Davis, HT, 2000) |
| " The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy." | 6.72 | Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. ( Burden, AM; Stämpfli, D; Weiler, S, 2021) |
| "Methylphenidate has short-term positive effects on children and adolescents with CD." | 6.68 | Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. ( Abikoff, H; Ganeles, D; Klass, E; Klein, RG; Pollack, S; Seese, LM, 1997) |
| "Conduct disorder was significantly higher in patients with DP, whereas ODD was significantly higher in the DESR and non-ED groups (P < 0." | 5.46 | Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( Akyol Ardic, U; Ercan, ES; Kutlu, A, 2017) |
| "Methylphenidate treatment for ADHD and CD has acute effects on these processes." | 5.43 | Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder. ( Acheson, A; Dougherty, DM; Hill-Kapturczak, N; Mathias, CW; Olvera, RL; Ryan, SR, 2016) |
| "Baseline oppositional defiant disorder (ODD) and conduct disorder (CD) scores were correlated with the CGI-S score; however, no association was found between core ADHD symptom severity and the CGI-S score." | 5.40 | Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder. ( Bilgiç, A; Hergüner, S; Yılmaz, S, 2014) |
| " To determine (1) the serum baseline daily variations and nocturnal excretion of melatonin in ADHD subtypes and (2) the effect of chronic administration of methylphenidate, as well as the effects on symptomatology, 136 children with ADHD (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision: DSM-IV-TR criteria) were divided into subgroups using the "Children's Depression Inventory" (CDI)." | 5.19 | Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum melatonin concentration between ADHD subtypes. ( Cubero-Millán, I; Fernández-López, L; Luna-del-Castillo, JD; Machado-Casas, I; Martínez-Serrano, S; Molina-Carballo, A; Muñoz-Hoyos, A; Ruiz-López, A; Tortosa-Pinto, P; Uberos, J, 2014) |
| "This study investigated the safety and efficacy of adding the atypical antipsychotic quetiapine to ongoing OROS methylphenidate treatment for adolescents with comorbid ADHD and severe aggression that were incompletely responsive to methylphenidate monotherapy." | 5.12 | Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. ( Bohnstedt, BN; Dunn, DW; Giauque, AL; Kronenberger, WG; Lafata, DE; Maxey, LE, 2007) |
| "A pilot comparison of the safety and efficacy of methylphenidate (MPH) combined with clonidine, clonidine monotherapy, or MPH monotherapy in 6- to 16-year-old children diagnosed with attention deficit hyperactivity disorder (ADHD) and comorbid aggressive oppositional defiant disorder or conduct disorder was completed." | 5.09 | A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. ( Barkley, RA; Connor, DF; Davis, HT, 2000) |
| "The aim of this study was to compare the effect of methylphenidate (MPH) versus MPH + parent training in children with ADHD and oppositional defiant disorder/conduct disorder (ODD/CD) over a 12-month period." | 3.80 | No beneficial effects of adding parent training to methylphenidate treatment for ADHD + ODD/CD children: a 1-year prospective follow-up study. ( Ardic, UA; Durak, S; Ercan, ES; Kutlu, A, 2014) |
| " The average dosage of MPH in the group with ADHD was 0." | 2.84 | Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder. ( Gokce, S; Gumustas, F; Sabuncuoglu, O; Yilmaz, I; Yulaf, Y, 2017) |
| "3%) of 65 children was reduced sufficiently after stimulant dosage adjustment and behavioral therapy to preclude adjunctive medication." | 2.75 | Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. ( Blader, JC; Jensen, PS; Kafantaris, V; Pliszka, SR; Schooler, NR, 2010) |
| " Children whose aggressive behavior persisted at the conclusion of the lead-in phase were randomly assigned to receive double-blind, flexibly dosed divalproex or a placebo adjunctive to stimulant for 8 weeks." | 2.74 | Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. ( Blader, JC; Jensen, PS; Kafantaris, V; Pliszka, SR; Schooler, NR, 2009) |
| " The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy." | 2.72 | Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. ( Burden, AM; Stämpfli, D; Weiler, S, 2021) |
| "Methylphenidate has short-term positive effects on children and adolescents with CD." | 2.68 | Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. ( Abikoff, H; Ganeles, D; Klass, E; Klein, RG; Pollack, S; Seese, LM, 1997) |
| "Although the relationship between attention-deficit/hyperactivity disorder (ADHD) and transport accidents has been shown, there is limited information on the relationship between medication and dose-response effects and transport accident risk." | 1.62 | Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH. ( Chen, VC; Chen, YL; Gossop, M; Liu, YC; Yang, YH, 2021) |
| "Conduct disorder (CD) and oppositional defiant disorder (ODD), collectively termed disruptive behavior disorders (DBDs), are a major cause of impairment and suffering in those affected by these conditions and their families and communities." | 1.48 | Does Methylphenidate Normalize Brain Dysfunction During Fear Learning in Adolescents With Disruptive Behavior Disorders? ( Fairchild, G, 2018) |
| "Conduct disorder was significantly higher in patients with DP, whereas ODD was significantly higher in the DESR and non-ED groups (P < 0." | 1.46 | Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( Akyol Ardic, U; Ercan, ES; Kutlu, A, 2017) |
| "Methylphenidate treatment for ADHD and CD has acute effects on these processes." | 1.43 | Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder. ( Acheson, A; Dougherty, DM; Hill-Kapturczak, N; Mathias, CW; Olvera, RL; Ryan, SR, 2016) |
| "Diagnoses of SUD and alcohol abuse were obtained from The Danish Psychiatric Central Register." | 1.40 | ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study. ( Dalsgaard, S; Frydenberg, M; Mortensen, PB; Thomsen, PH, 2014) |
| "Baseline oppositional defiant disorder (ODD) and conduct disorder (CD) scores were correlated with the CGI-S score; however, no association was found between core ADHD symptom severity and the CGI-S score." | 1.40 | Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder. ( Bilgiç, A; Hergüner, S; Yılmaz, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.65) | 18.7374 |
| 1990's | 4 (9.30) | 18.2507 |
| 2000's | 17 (39.53) | 29.6817 |
| 2010's | 18 (41.86) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Stämpfli, D | 1 |
| Weiler, S | 1 |
| Burden, AM | 1 |
| Liu, YC | 1 |
| Chen, VC | 1 |
| Yang, YH | 1 |
| Chen, YL | 1 |
| Gossop, M | 1 |
| Gumustas, F | 1 |
| Yilmaz, I | 1 |
| Yulaf, Y | 1 |
| Gokce, S | 1 |
| Sabuncuoglu, O | 2 |
| Gnanavel, S | 1 |
| Fairchild, G | 1 |
| Zoratto, F | 1 |
| Franchi, F | 1 |
| Macrì, S | 1 |
| Laviola, G | 1 |
| Dalsgaard, S | 1 |
| Mortensen, PB | 1 |
| Frydenberg, M | 1 |
| Thomsen, PH | 1 |
| Yılmaz, S | 1 |
| Bilgiç, A | 1 |
| Hergüner, S | 1 |
| Blader, JC | 3 |
| Pliszka, SR | 4 |
| Kafantaris, V | 3 |
| Foley, CA | 1 |
| Crowell, JA | 1 |
| Carlson, GA | 1 |
| Sauder, CL | 1 |
| Margulies, DM | 1 |
| Sinha, C | 1 |
| Sverd, J | 1 |
| Matthews, TL | 1 |
| Bailey, BY | 1 |
| Daviss, WB | 1 |
| Javelot, H | 1 |
| Glay-Ribau, C | 1 |
| Ligier, F | 1 |
| Weiner, L | 1 |
| Didelot, N | 1 |
| Messaoudi, M | 1 |
| Socha, M | 1 |
| Body-Lawson, F | 1 |
| Kabuth, B | 1 |
| Rubia, K | 1 |
| Alegría, AA | 1 |
| Brinson, H | 1 |
| Cubero-Millán, I | 1 |
| Molina-Carballo, A | 1 |
| Machado-Casas, I | 1 |
| Fernández-López, L | 1 |
| Martínez-Serrano, S | 1 |
| Tortosa-Pinto, P | 1 |
| Ruiz-López, A | 1 |
| Luna-del-Castillo, JD | 1 |
| Uberos, J | 1 |
| Muñoz-Hoyos, A | 1 |
| Helseth, SA | 1 |
| Waschbusch, DA | 3 |
| Gnagy, EM | 1 |
| Onyango, AN | 1 |
| Burrows-MacLean, L | 1 |
| Fabiano, GA | 1 |
| Coles, EK | 1 |
| Chacko, A | 1 |
| Wymbs, BT | 1 |
| Walker, KS | 1 |
| Wymbs, FA | 1 |
| Garefino, A | 1 |
| Massetti, GM | 1 |
| Robb Mazzant, J | 1 |
| Hoffman, MT | 1 |
| Waxmonsky, JG | 1 |
| Nichols-Lopez, K | 1 |
| Pelham, WE | 3 |
| Dougherty, DM | 1 |
| Olvera, RL | 1 |
| Acheson, A | 1 |
| Hill-Kapturczak, N | 1 |
| Ryan, SR | 1 |
| Mathias, CW | 1 |
| Kutlu, A | 2 |
| Akyol Ardic, U | 1 |
| Ercan, ES | 3 |
| Karama, S | 1 |
| Ben Amor, L | 1 |
| Grizenko, N | 2 |
| Ciampi, A | 1 |
| Mbekou, V | 1 |
| Ter-Stepanian, M | 2 |
| Lageix, P | 1 |
| Baron, C | 1 |
| Schwartz, G | 1 |
| Joober, R | 2 |
| King, S | 2 |
| Frankland, BW | 1 |
| Andrade, BF | 1 |
| Jacques, S | 1 |
| Corkum, PV | 1 |
| Dopheide, JA | 1 |
| Schooler, NR | 2 |
| Jensen, PS | 2 |
| Rothermel, B | 1 |
| Poustka, L | 1 |
| Banaschewski, T | 2 |
| Becker, K | 1 |
| Zappitelli, M | 1 |
| Ardic, UA | 1 |
| Durak, S | 1 |
| Tamm, L | 1 |
| Trello-Rishel, K | 1 |
| Riggs, P | 1 |
| Nakonezny, PA | 1 |
| Acosta, M | 1 |
| Bailey, G | 1 |
| Winhusen, T | 1 |
| Hazell, PL | 1 |
| Stuart, JE | 1 |
| ZIMMERMAN, FT | 1 |
| BURGEMEISTER, BB | 1 |
| GROSS, MD | 1 |
| WILSON, WC | 1 |
| Yamashita, T | 1 |
| Wada, Y | 1 |
| Shiomi, S | 1 |
| Nakane, A | 1 |
| Taylor, E | 1 |
| Döpfner, M | 2 |
| Sergeant, J | 1 |
| Asherson, P | 1 |
| Buitelaar, J | 1 |
| Coghill, D | 1 |
| Danckaerts, M | 1 |
| Rothenberger, A | 1 |
| Sonuga-Barke, E | 1 |
| Steinhausen, HC | 1 |
| Zuddas, A | 1 |
| Varan, A | 1 |
| Deniz, U | 1 |
| Craig, R | 1 |
| Kronenberger, WG | 2 |
| Giauque, AL | 2 |
| Lafata, DE | 1 |
| Bohnstedt, BN | 1 |
| Maxey, LE | 1 |
| Dunn, DW | 2 |
| Sinzig, J | 1 |
| Lehmkuhl, G | 1 |
| Uebel, H | 1 |
| Schmeck, K | 1 |
| Poustka, F | 1 |
| Gerber, WD | 1 |
| Günter, M | 1 |
| Knölker, U | 1 |
| Gehrke, M | 1 |
| Hässler, F | 1 |
| Resch, F | 1 |
| Brünger, M | 1 |
| Ose, C | 1 |
| Fischer, R | 1 |
| Maia, CR | 1 |
| Matte, BC | 1 |
| Ludwig, HT | 1 |
| Rohde, LA | 1 |
| Szobot, CM | 1 |
| Bukstein, O | 1 |
| Handen, BL | 1 |
| Janosky, J | 1 |
| McAuliffe, S | 1 |
| Klein, RG | 1 |
| Abikoff, H | 1 |
| Klass, E | 1 |
| Ganeles, D | 1 |
| Seese, LM | 1 |
| Pollack, S | 1 |
| Kolko, DJ | 1 |
| Bukstein, OG | 1 |
| Barron, J | 1 |
| Weller, EB | 1 |
| Rowan, A | 1 |
| Elia, J | 1 |
| Weller, RA | 1 |
| Connor, DF | 1 |
| Barkley, RA | 1 |
| Davis, HT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder[NCT00228046] | Phase 4 | 40 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD[NCT00794625] | Phase 4 | 270 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Virtual Reality Attention Management Program for Improving Attention in Children[NCT03221244] | 50 participants (Anticipated) | Interventional | 2016-06-02 | Recruiting | |||
| Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)[NCT00483106] | Phase 4 | 885 participants (Actual) | Interventional | 1999-11-30 | Completed | ||
| Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)[NCT00264797] | Phase 3 | 303 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Multimodal Treatment Study of Children With ADHD[NCT00000388] | Phase 4 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DSM IV ADHD Rating Scale (ADHD-RS) adolescent informant, ascertained at baseline and weekly throughout the 16 week study. This scale is an 18-item symptom checklist of self-reported adolescent ADHD symptoms. Symptoms are scored as None (0), Mild (1), Moderate (2), and Severe (3), with a summary total of scores for the 18 symptoms. Possible scores range from 0 to 54, with higher scores indicating greater severity. Outcome is measured as the decrease in total severity score over time. (NCT00264797)
Timeframe: baseline and 20 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Methylphenidate | -20.6 |
| Methylphenidate (Placebo) | -21.8 |
Assessed by pill counts in conjunction with weekly review of subjects' medication diaries and self-reported medication compliance. (NCT00264797)
Timeframe: 20 weeks
| Intervention | pills (Mean) |
|---|---|
| Methylphenidate | 15.4 |
| Methylphenidate (Placebo) | 9.7 |
The change in number of days of substance use from baseline to end of the trial. The number of days of non-tobacco drug/alcohol ascertained using standard timeline follow back (TLFB) procedures. (NCT00264797)
Timeframe: 20 weeks
| Intervention | days (Mean) |
|---|---|
| Methylphenidate | -5.7 |
| Methylphenidate (Placebo) | -5.2 |
The mean number of negative urine drug screens (UDS). (NCT00264797)
Timeframe: 20 weeks
| Intervention | negative UDS (Mean) |
|---|---|
| Methylphenidate | 3.8 |
| Methylphenidate (Placebo) | 2.8 |
7 reviews available for methylphenidate and Conduct Disorder
| Article | Year |
|---|---|
Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.
Topics: Attention Deficit Disorder with Hyperactivity; Combined Modality Therapy; Comorbidity; Conduct Disor | 2021 |
Brain abnormalities in attention-deficit hyperactivity disorder: a review.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; A | 2014 |
Attention-deficit-hyperactivity disorder: an update.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Antidepressive Agents, Second-Generati | 2009 |
[Conduct disorder confined to the family context].
Topics: Adolescent; Central Nervous System Stimulants; Child; Child, Preschool; Conduct Disorder; Domestic V | 2003 |
[Conduct disorder, unsocialized and socialized].
Topics: Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nerv | 2003 |
Attention deficit hyperactivity disorder and substance use disorders.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimula | 2008 |
Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Child; Child D | 1999 |
19 trials available for methylphenidate and Conduct Disorder
| Article | Year |
|---|---|
Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous Sys | 2017 |
Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Aggression; Antisocial Personality Disorder; Attention Deficit and Disruptive Behavior D | 2013 |
Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Aggression; Antisocial Personality Disorder; Attention Deficit and Disruptive Behavior D | 2013 |
Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Aggression; Antisocial Personality Disorder; Attention Deficit and Disruptive Behavior D | 2013 |
Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Aggression; Antisocial Personality Disorder; Attention Deficit and Disruptive Behavior D | 2013 |
Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum melatonin concentration between ADHD subtypes.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
Effects of behavioral and pharmacological therapies on peer reinforcement of deviancy in children with ADHD-only, ADHD and conduct problems, and controls.
Topics: Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; | 2015 |
Factor structure of the restricted academic situation scale: implications for ADHD.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2009 |
Social information processing in elementary-school aged children with ADHD: medication effects and comparisons with typical children.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
Topics: Adolescent; Aggression; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorders; Atten | 2009 |
Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders.
Topics: Anxiety Disorders; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder w | 2010 |
Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2010 |
Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; C | 2013 |
A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children.
Topics: Adolescent; Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disor | 2003 |
Self-handicapping prior to academic-oriented tasks in children with attention deficit/hyperactivity disorder (ADHD): medication effects and comparisons with controls.
Topics: Adolescent; Aptitude; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 2007 |
Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central | 2007 |
Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 2007 |
Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adult; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit | 2008 |
Long-term follow-up of children with mental retardation/borderline intellectual functioning and ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 1997 |
Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Conduct D | 1997 |
Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 1999 |
A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder.
Topics: Adolescent; Adrenergic alpha-Agonists; Aggression; Attention Deficit Disorder with Hyperactivity; Ce | 2000 |
17 other studies available for methylphenidate and Conduct Disorder
| Article | Year |
|---|---|
Association of psychiatric comorbidities with the risk of transport accidents in ADHD and MPH.
Topics: Accidents, Traffic; Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Defic | 2021 |
Tardive Oculogyric Crisis With Low-Dose Antipsychotic in an Adolescent: A Case Report.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2018 |
Does Methylphenidate Normalize Brain Dysfunction During Fear Learning in Adolescents With Disruptive Behavior Disorders?
Topics: Adolescent; Adult; Attention Deficit and Disruptive Behavior Disorders; Brain; Child; Conduct Disord | 2018 |
Methylphenidate administration promotes sociability and reduces aggression in a mouse model of callousness.
Topics: Aggression; Animals; Attention; Conduct Disorder; Disease Models, Animal; Dopamine Uptake Inhibitors | 2019 |
ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study.
Topics: Adolescent; Adult; Age Factors; Alcoholism; Attention Deficit Disorder with Hyperactivity; Central N | 2014 |
Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2014 |
Methylphenidate-risperidone combination in child psychiatry: A retrospective analysis of 44 cases.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; Conduct Disorder | 2014 |
Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimula | 2016 |
Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder.
Topics: Adolescent; Affective Symptoms; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; C | 2017 |
[Bipolar disorders as co-morbidity in childhood and adolescence--underdiagnosed or overinterpreted? Therapy of a 14-year-old boy with hyperkinetic conduct disorder and hypomania].
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; A | 2010 |
No beneficial effects of adding parent training to methylphenidate treatment for ADHD + ODD/CD children: a 1-year prospective follow-up study.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Conduct Diso | 2014 |
Action of methyl-phenidylacetate (ritalin) and reserpine in behavior disorders in children and adults.
Topics: Behavior; Conduct Disorder; Mental Disorders; Methylphenidate; Reserpine | 1958 |
BEHAVIOR DISORDERS OF CHILDREN WITH CEREBRAL DYSRHYTHMIAS; SUCCESSFUL TREATMENT OF SUBCONVULSIVE DYSRHYTHMIA WITH ANTICONVULSANTS.
Topics: Acetazolamide; Amphetamine; Amphetamines; Anticonvulsants; Child; Child Behavior Disorders; Conduct | 1964 |
European clinical guidelines for hyperkinetic disorder -- first upgrade.
Topics: Alleles; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Ch | 2004 |
Effects of combined treatment on Turkish children diagnosed with attention-deficit/hyperactivity disorder: a preliminary report.
Topics: Adolescent; Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Conduct Diso | 2005 |
Risperidone-to-methylphenidate switch reaction in children: three cases.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit and Disruptive Behavior | 2007 |
Development and validation of the outburst monitoring scale for children and adolescents.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central | 2007 |